Diagnosis and treatment of hyperhomocysteinemia.

M. E. Keebler, C. De Souza, V. Fonseca

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Hyperhomocysteinemia has emerged as an important risk factor for cardiovascular disease. However, its place in clinical practice is somewhat unclear, due to the lack of clinical trials documenting the benefit of treatment on reducing cardiovascular events. Vitamin therapy, particularly with folic acid, reduces plasma homocysteine significantly and improves other surrogate markers of cardiovascular risk such as endothelial function. Although a consensus is lacking on the right approach to diagnosis and treatment of this risk factor, we have suggested an algorithm based on data from clinical studies. We are optimistic that such an approach will be helpful for the clinician until clinical trials, with cardiovascular events as endpoints, are completed.

Original languageEnglish (US)
Pages (from-to)54-63
Number of pages10
JournalCurrent atherosclerosis reports
Issue number1
StatePublished - Jan 2001
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Diagnosis and treatment of hyperhomocysteinemia.'. Together they form a unique fingerprint.

Cite this